Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24163239 | 0.84 | LMNA (0.36) | LMNATDP1 | |
| SCHEMBL19737412 | 0.79 | LMNA (0.33) | LMNATDP1 | |
| SCHEMBL21316101 | 0.75 | — | — | |
| SCHEMBL26329249 | 0.72 | LMNA (0.31) | LMNATDP1 | |
| SCHEMBL539128 | 0.72 | — | — | |
| SCHEMBL20801765 | 0.71 | LMNA (0.33) | LMNATDP1 | |
| Bromide SCHEMBL28350490 | 0.70 | LMNA (0.48) | LMNATDP1 | |
| SCHEMBL19902537 | 0.69 | LMNA (0.36) | LMNATDP1 | |
| SCHEMBL24338657 | 0.68 | LMNA (0.35) | LMNATDP1 | |
| SCHEMBL23074736 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105503-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105503-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | LMNA 825/4885TDP1 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.